An anti-inflammatory diet as treatment for inflammatory bowel disease: a case series report by Olendzki, Barbara C. et al.
University of Massachusetts Medical School 
eScholarship@UMMS 
Open Access Articles Open Access Publications by UMMS Authors 
2014-01-16 
An anti-inflammatory diet as treatment for inflammatory bowel 
disease: a case series report 
Barbara C. Olendzki 
University of Massachusetts Medical School 
Et al. 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/oapubs 
 Part of the Dietetics and Clinical Nutrition Commons, Digestive System Diseases Commons, 
Gastroenterology Commons, and the Nutritional Epidemiology Commons 
Repository Citation 
Olendzki BC, Silverstein T, Persuitte GM, Ma Y, Baldwin K, Cave DR. (2014). An anti-inflammatory diet as 
treatment for inflammatory bowel disease: a case series report. Open Access Articles. https://doi.org/
10.1186/1475-2891-13-5. Retrieved from https://escholarship.umassmed.edu/oapubs/2433 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Open Access Articles 
by an authorized administrator of eScholarship@UMMS. For more information, please contact 
Lisa.Palmer@umassmed.edu. 
RESEARCH Open Access
An anti-inflammatory diet as treatment for
inflammatory bowel disease: a case series report
Barbara C Olendzki1*, Taryn D Silverstein2, Gioia M Persuitte1, Yunsheng Ma1, Katherine R Baldwin3
and David Cave2
Abstract
Background: The Anti-Inflammatory Diet (IBD-AID) is a nutritional regimen for inflammatory bowel disease (IBD)
that restricts the intake of certain carbohydrates, includes the ingestion of pre- and probiotic foods, and modifies
dietary fatty acids to demonstrate the potential of an adjunct dietary therapy for the treatment of IBD.
Methods: Forty patients with IBD were consecutively offered the IBD-AID to help treat their disease, and were
retrospectively reviewed. Medical records of 11 of those patients underwent further review to determine
changes in the Harvey Bradshaw Index (HBI) or Modified Truelove and Witts Severity Index (MTLWSI), before and
after the diet.
Results: Of the 40 patients with IBD, 13 patients chose not to attempt the diet (33%). Twenty-four patients had
either a good or very good response after reaching compliance (60%), and 3 patients’ results were mixed (7%).
Of those 11 adult patients who underwent further medical record review, 8 with CD, and 3 with UC, the age
range was 19–70 years, and they followed the diet for 4 or more weeks. After following the IBD-AID, all (100%)
patients were able to discontinue at least one of their prior IBD medications, and all patients had symptom reduction
including bowel frequency. The mean baseline HBI was 11 (range 1–20), and the mean follow-up score was 1.5 (range
0–3). The mean baseline MTLWSI was 7 (range 6–8), and the mean follow-up score was 0. The average decrease in the
HBI was 9.5 and the average decrease in the MTLWSI was 7.
Conclusion: This case series indicates potential for the IBD-AID as an adjunct dietary therapy for the treatment of IBD.
A randomized clinical trial is warranted.
Keywords: Diet, Inflammatory bowel disease, Nutrition
Introduction
Crohn’s disease (CD) and ulcerative colitis (UC) are two
chronic inflammatory diseases of the gastrointestinal
tract, collectively known as inflammatory bowel disease
(IBD). Each is distinct in its presentation and course of
disease, and both are chronically relapsing illnesses. Des-
pite histological differences between the two diseases,
dietary therapy (with the exception of known efficacy of
enteral therapy and CD) has often been similar for both
[1], involving options that include increased fluids,
avoidance of fatty foods, dietary fiber, and dairy products
if lactose intolerant. Others have ingested nothing by
mouth for a period of time, and used tube feeding with
elemental diets [2]. Presently, an alteration of the intes-
tinal microbiome is believed to be a major factor in the
pathogenesis of IBD, and this change provides a possible
pathway for dietary manipulations of the microbiome
that may reduce inflammation in these conditions [3,4].
The goals for treatment of IBD are the induction of re-
mission, maintenance of remission, reduction in the need
for long-term use of corticosteroids, improved quality of
life, and improved prognosis. The mainstays of current
treatment comprise of anti-inflammatory agents including
corticosteroids, immunomodulators, and biologic agents.
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There are surgical options including colectomy, which
while curative for patients with UC, can result in a pouch
or end ileostomy in approximately 30% of patients [5].
Neither of these surgical options is without complications
and up to 70% of patients with a pouch may develop pou-
chitis [6,7]. An even higher percentage of CD patients
need surgery, with upward of 80% of patients requiring
surgical resection that is not necessarily curative [5].
Until recently, the investigation of nutritional ap-
proaches in treating the diseases have been largely lim-
ited to the use of enteral and total parenteral nutrition
with the aim of providing bowel rest [8,9]. Dietary whole
food recommendations for CD and UC are poorly devel-
oped, even though patients often ask for advice with
their diet [10]. To prepare clinicians for the complex
management of patients with IBD, Brown et al. pub-
lished dietary guidelines to fill this gap, [2] compiling a
summary of suggestions from reputable organizations,
concluding that no specific diet currently exists for pa-
tients with IBD. Most dietary guidelines, though varied
in scope and complexity, indicate that limiting lactose,
excess fat, excess carbohydrates, and reducing fiber in
the diet is necessary, particularly during flares of disease
[2]. Mineral and vitamin supplementation may or may
not assist with nutrient deficiencies and malabsorption.
In addition, many patients also experience other food
intolerances [11,12]. To provide a dietary therapy ap-
proach addressing nutrient adequacy, malabsorption
issues, and symptoms, we developed the IBD-Anti-
Inflammatory Diet, or IBD-AID [13-15]. The diet was
offered to patients who were refractory to pharmaco-
logical therapy, or treatment was not as effective as
desired. This is a retrospective case series to demon-
strate the beneficial effects of the IBD-AID on a small
number of patients.
Materials and methods
Patients
Forty patients received instructions for the diet, 37 saw the
nutritionist, and 3 were seen only by gastroenterologists.
Medical records review was approved by the Institutional
Review Board (IRB) of the University of Massachusetts
Medical School. Eligibility for this further review included
seeing an IRB-approved gastroenterologist and dietitian in
clinic, endoscopically-diagnosed IBD and failure of drug
treatment, persistent symptoms, or reluctance to proceed
with other options (Table 1). Medical records of the eleven
patients for whom we had complete data and used the
IBD-AID to help treat their disease were retrospectively
reviewed and their progress was assessed using the Harvey
Bradshaw (HBI) and Modified Truelove and Witts Severity
Index (MTLWSI) scoring systems [16,17] applied before
and during the use of the IBD-AID. Review of these pa-
tients included clinic notes from gastroenterologists,
primary care physicians, nutritionists, surgeons, hos-
pital admission and discharge summaries, as well as la-
boratory data (i.e.; hematocrit, albumin, erythrocyte
sedimentation rate (ESR), C-reactive protein (CRP), drug
concentration levels, imaging studies, and endoscopic
evaluation. An HBI for CD patients or MTLWSI for UC
patients was included or estimated from information pro-
vided by clinic notes. The data was compared before diet-
ary treatment, and evaluated 1–3 months after patients
stated they followed the IBD-AID.
Table 1 Participant demographics, medications, and disease indices
Age Sex Disease Prior treatment includes Recent treatment HBI/MTLWSI before HBI/MTLWSI after
39 F CD ASA, IM, B ASA + IBD-AID HBI 12 3
47 F CD S, IM, B S(taper) + IBD-AID HBI 9 2
39 F CD S,IM IM + IBD-AID HBI 12 2
24 F CD S,ASA, IM, B S(taper) IM + IBD-AID HBI 15 0
39 M CD IM, B IBD + AID HBI 20 0
40 M CD S,ASA, IM IM + IBD-AID HBI 15 2
41 M CD ASA, IM IM + IBD-AID HBI 4 2
37 F CD S,ASA, B, elemental diet B + IBD-AID HBI 1 1; histologic remission
69 M UC ASA, IM, B ASA, IM + IBD-AID MTLWSI n/d 2; improved
19 F UC S, ASA, IM, B ASA, IBD-AID MTLWSI 6 0
70 F UC ASA, IM, B B + IBD-AID MTLWSI 8 0
Legend:
ASA = 5-Aminosalycylic acid agent.
IM = Immunomodulator.
B = Biologic.
S = Steroid.
IBD-AID = Inflammatory Bowel Disease-Anti-Inflammatory Diet.
HBI = Harvey Bradshaw Index.
MTLWSISI = Modified TrueLove and Witts Severity Index.
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The diet
The goal of the IBD-AID is to assist with a decreased
frequency and severity of flares, obtain and maintain re-
mission. Dysbiosis, or altered bacterial flora, is one of
the theories behind the development of IBD-AID, in that
certain carbohydrates in the lumen of the gut provide
pathogenic bacteria a substrate on which to proliferate
[17-21]. The IBD-AID has five basic components: the
first of which is the modification of certain carbohy-
drates, (including lactose, and refined or processed com-
plex carbohydrates) the second places strong emphasis
on the ingestion of pre- and probiotics (e.g.; soluble
fiber, leeks, onions, and fermented foods) to help restore
the balance of the intestinal flora [22-25], and the third
distinguishes between saturated, trans, mono- and poly-
unsaturated fats [26-29], the fourth encourages a review
of the overall dietary pattern, detection of missing nutri-
ents, and identification of intolerances. The last compo-
nent modifies the textures of the foods (e.g.; blenderized,
ground, or cooked) as needed (per patient symptomol-
ogy, see Table 2) to improve absorption of nutrients and
minimize intact fiber. The phases indicated in Table 2
are examples of the modification of texture complexity,
so that dietitian and patient can expand the diet as the
patient’s tolerance and absorption improves. Some sensi-
tivities common to many patients (not just those with
IBD), are eased through supplementation of digestive en-
zymes or avoidance. A senior dietitian advised the pa-
tient and either family or spouse regarding the details of
the diet during regular clinic visits. Patients taking sup-
plements (probiotics, vitamin/minerals, omega-3 fatty
acids) were advised to continue or discontinue, depend-
ing on the needs of the individual and the dietary intake.
The IBD-AID consists of lean meats, poultry, fish,
omega-3 eggs, particular sources of carbohydrate, select
fruits and vegetables, nut and legume flours, limited
aged cheeses (made with active cultures and enzymes),
fresh cultured yogurt, kefir, miso and other cultured
products (rich with certain probiotics) and honey. Prebi-
otics, in the form of soluble fiber (containing beta-
glucans and inulin, such as bananas, oats, blended
chicory root, and flax meal) are suggested. In addition,
the patient is advised to begin at a texture phase of the
diet matching with symptomology, starting with phase
one if in an active flare. Many patients require foods to
be softened and textures mechanically altered by pu-
reeing the foods, and avoiding foods with stems and
seeds when starting the diet (see phases 1–3 of Table 2),
as intact fiber can be problematic for those with strictures
and highly active mucosal inflammation. Some patients
will require lifelong avoidance of intact fiber. Food irri-
tants are not limited to intact fiber, but may include cer-
tain foods, processing agents and flavorings to which IBD
patients may be reactive.
For the purposes of this study, compliance was deter-
mined by food records (patient self-report), and included
all food components for the duration of the study. After
the first visit with the dietitian, patients were asked to
keep detailed food records, along with time and record-
ing of symptoms (on a scale of 0–5), with follow-up ap-
pointments occurring 2–3 weeks after the initial consult.
Symptoms included a subjective assessment of bloating,
pain, diarrhea, urgency, bleeding, and fatigue. Other in-
fluences to health that were recorded by patients in-
cluded perceived stress, and origin of food intake. Most
patients indicated difficulty in understanding and adhering
to the diet initially, while tracking trends of symptomatic
progress. The form and type of foods recommended in
the beginning were based on the severity of symptoms
reported, with the goal to deliver nutrients even if the
patient started the diet while in a flare. As symptoms
improved, patients were advanced to more whole
foods, but within the guidelines of the IBD-AID. One of
the patients did not improve within the first 2–3 weeks,
and the diet was reviewed for foods of intolerance. In this
case, the patient who continued to experience symptoms
(loose bowels, dyspepsia and bloating) improved through
stronger adherence and changing the texture/form of
foods consumed. All patients were then advanced cau-
tiously as symptoms improved.
Clinical assessment
The HBI was used to assess study patients with CD. The
HBI is a simplified, less cumbersome alternative to the
Crohn’s Disease Activity Index (CDAI), and is designed
to make data collection and calculation easier, with
greater application to clinical practice since it is based
on the last 24 hours of data [17]. A prospective study of
112 patients with Crohn’s disease showed that the CDAI
and HBI scores were highly correlated (r = 0.93) [17].
Our analyses define HBI remission as an HBI score of
less than or equal to 4 points, and HBI response as a de-
crease in HBI score of greater than or equal to 3 points.
The MTLWSI was used for patients with UC. First de-
scribed in 1990 by Lichtiger and colleagues [16] in a trial
for the treatment of UC, the MTLWSI includes a scor-
ing system ranging from 0–21 points, and clinical re-
sponse is defined as a decrease from the baseline score
of 50%, or greater or less than 10 on 2 consecutive days.
Clinical remission criteria was determined by a MTWSI
of less than or equal to 2, and clinical response was de-
fined as a reduction from baseline in the MTWSI of
greater than or equal to 2 points [30].
Results
Out of the original 40 patients, 37 were seen by the
dietitian. Of those, 13 did not attend any follow-up
visits. Three had an ambivalent or negative response to
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Table 2 IBD-AID food phase chart
Phase type Phase I Phase II Phase III Phase IV
Soft, well-cooked or cooked then
pureed foods, no seeds
Soft Textures: well-cooked or pureed
foods, no seeds, choose floppy or
tender foods
May still need to avoid stems, choose
floppy greens or other greens depending
on individual tolerance
If in remission with no strictures
Vegetables Butternut Squash, Pumpkin, Sweet
Potatoes, Onions
Carrots, Zucchini, Eggplant, Peas, Snow
peas, Spaghetti squash, Green beans,
Yellow beans, Microgreens (2 week old
baby greens), Watercress, Arugula, Fresh
flat leaf parsley and cilantro, Seaweed,
Algae
Butter lettuce, Baby spinach, Peeled cucumber,
Olives, Leeks Bok Choy, Bamboo shoots, Collard
greens, Beet greens, Sweet peppers, Kale,
Fennel bulb
Artichokes, Asparagus, Tomatoes,
Lettuce, Brussels sprouts, Beets,
Cabbage, Kohlrabi, Rhubarb, Pickles,
Spring onions, Water chestnuts,
Celery, Celeriac, Cauliflower, Broccoli,
Radish, Green pepper, Hot pepper
Pureed vegetables: Mushrooms,
Phase II vegetables (pureed)
Pureed vegetables: all except cruciferous Pureed vegetables: all from Phase IV, Kimchi
Fruits Banana, Papaya, Avocado, Pawpaw Watermelon (seedless), Mangoes, Honeydew,
Cantaloupe, May need to be cooked: Peaches,
Plums, Nectarines, Pears, (Phase III fruits are
allowed if pureed and seeds are strained out)
Strawberries, Cranberries, Blueberries, Apricots,
Cherries, Coconut, Lemons, Limes, Kiwi, Passion
fruit, Blackberries, Raspberries, Pomegranate
(May need to strain seeds from berries)
Grapes, Grapefruit, Oranges, Currants,
Figs, Dates, Apples (best cooked),
Pineapple, Prunes
Meats and fish All fish (no bones), Sardines (small
bones ok), Turkey and ground beef,
Chicken, Eggs
Scallops Lean cuts of Beef, Lamb, Duck, Goose Shrimp, Prawns, Lobster
Non dairy unsweetened Coconut milk, Almond milk, Oat
milk, Soy milk
Dairy, unsweetened Yogurt, Kefir Farmers cheese (dry curd cottage cheese),
Cheddar cheese
Aged cheeses
Nuts/Oils/Legumes/Fats Miso (refrigerated), Tofu, Olive oil,
Canola oil, Flax oil, Hemp oil,
Walnut oil, Coconut oil
Almond flour, Peanut flour, Soy flour, Sesame
oil, Grapeseed oil, Walnut oil, Pureed nuts,
Safflower oil, Sunflower oil
Whole nuts, Soybeans, Bean flours, Nut butters,
Well-cooked lentils (pureed), Bean purees
(e.g. hummus)
Whole beans and lentils
Grains Ground flax or Chia Seeds (as
tolerated)
Steel cut oats (well-cooked as oatmeal) Rolled well-cooked oats
Spices Basil, Sage, Oregano, Salt, Nutmeg,
Cumin, Cinnamon, Turmeric, Saffron,
Mint, Bay leaves, Tamari (wheat free
soy sauce), Fenugreek tea, Fennel
tea, Vanilla
Dill, Thyme, Rosemary Tarragon, Cilantro, Basil,
Parsley
Mint, Ginger, Garlic (minced), Paprika, Chives,
Daikon, Mustard
Wasabi, Tamarind, Horseradish,
Fenugreek, Fennel
Sweeteners Stevia, Maple syrup, Honey (local),
Unsweetened fruit juice
Lemon and lime juice
Misc. Capsule or liquid supplements,
Cocoa powder
Baking powder (no cornstarch), Baking soda,
Unflavored gelatin
Ghee, Light mayonnaise, Vinegar Ketchup (sugar free), Hot sauce
(sugar free)
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the diet, and 24 had a good or very good response to the
diet, as measured by self-report of symptoms and com-
pliance with the diet through food records. Of the pa-
tients reporting improvement, they were all able to
reach greater than 70% compliance to the diet. Of the 3
patients (2 with UC, 1 with CD) with ambivalent or
negative response, 2 were diagnosed with Clostridium
Difficile (C-diff ), and the other (UC) patient’s response
is unattributable.
The 11 patients, who met eligibility by IRB and had
complete data, underwent medical record review: 8 have
CD, 3 have UC, and age range was 19–70 years (see
Table 1). All patients used the diet for at least 4 weeks.
Before the dietary intervention, 7 patients (64%) had 1
or more drug treatment failures, meaning they had ad-
verse side effects, the medication had no effect, or the
medication had become ineffective over time. After
using the IBD-AID, which was the only additional inter-
vention added, all (100%) of the patients worked with
their gastroenterologists to downscale their medication
regimen and all (100%) of the patients had their IBD
symptoms reduced. Of the CD patients, the baseline
HBI averaged 11 (range 1 to 20), and after dietary inter-
vention, the HBI averaged 1.5 (range 0 to 3). The UC pa-
tients had a mean baseline score of MTLWSI of 7 (range
6 to 8, with one patient unable to report baseline), and
their mean follow-up score was 0. The mean decrease in
the HBI was 9.5 and the mean decrease in the MTLWSI
was 7 (Table 1).
Discussion
Our data suggest that at least some of our patients with
inflammatory bowel disease can benefit from the use of
the IBD-AID, particularly in terms of reducing symp-
tomatology and consequently a reduction in the use of
medication. A portion (33%) of patients who were of-
fered the diet declined initiation, and of those who de-
cided to participate, many encountered behavioral and
intellectual barriers that are to be expected with any
comprehensive change in dietary lifestyle. The assistance
of a partner also trained in the IBD-AID was clearly
beneficial [31]. In the current study, due to small num-
bers of patients and the case series study design, we
were unable to confirm our hypothesized mechanisms of
action by examining the impact of the IBD-AID on the
intestinal microbiome. However, as deep sequencing and
other techniques for defining the microbiome become
less expensive this may prove an objective measure of
the benefit not only of the IBD-AID, but other diets as
well; particularly if the microbiome can be shown to
normalize as mucosal healing occurs.
Studies have suggested that IBD results from an inappro-
priate activation of the mucosal immune system in a genet-
ically susceptible host [30]. The intraluminal gut flora
appears to play a role in the inflammatory response and
pathogenesis of IBD [32]. A study of patients with UC
revealed that bifidobacteria populations are approximately
30 times lower than that of healthy individuals, indicating a
dysbiosis that may potentially alter inflammatory responses
[33,34]. However, it is unclear whether the change in flora
is primary, or secondary to the disease. Diet has been
shown to influence the balance of the intestinal flora [35];
therefore, it is conceivable that altering the diet can impact
the inflammatory response [36].
Mucosal healing potential is another aspect of the IBD-
AID [37]. Minimizing irritants, while increasing nutrient
delivery in a phased manner, (see Table 2) according to pa-
tient symptomology is an important consideration to the
diet. This is derived from the success of treatment of IBD
with tube feeding as opposed to simply nothing by mouth
(NPO) [38]. Nutritional deficiencies can result from re-
duced oral intake, malabsorption, medication side effects
and systemic inflammation due to active disease [38,39].
In CD, the natural history of disease progression is a sig-
nificant increase in complicated disease (from <29% pa-
tients at initial diagnosis having stricturing or penetrating
disease to 88% of patients at 20 years) [40].
The Specific Carbohydrate Diet (SCD, from which the
IBD-AID was derived and augmented) was developed by
Dr. Sydney Valentine Haas and Dr. Merrill P Hass for
the treatment of celiac disease in the mid-20th century
[41], and was later popularized as a treatment for IBD
via the internet and lay population [42]. This nutritional
regimen eliminates all grains, and encourages ingestion
of probiotics in the form of homemade yogurt. The IBD-
AID diet is not designed around avoidance of gluten,
and strives to address other micro- and macronutrients
not addressed in the SCD. The food supply, processing
and transport of foods have changed dramatically since
the inception of the SCD. The IBD-AID also modifies
fatty acids, specifically decreasing the total and saturated
fats and eliminating hydrogenated oils, and encouraging
the increased intake of foods with omega-3 fatty acids.
The IBD-AID also differs from the SCD with the inclu-
sion of oats, since oats (and possibly other fermentable
grains that provide a substrate for probiotics) [43] ap-
pear to be well tolerated and indeed are useful in regula-
tion of bowel frequency and consistency [44].
The IBD-AID is a dietary pattern for which the mecha-
nism and efficacy have yet to be elucidated. Poorly digested
complex carbohydrates (even those with defined pre-biotic
properties) may lead to bacterial overgrowth and bowel
injury with increased intestinal permeability. The waste
products of fermentation of undigested carbohydrates
include methane, carbon dioxide, hydrogen, lactic and
acetic acid, which are all gastrointestinal irritants. The
carbohydrates allowed on the original diet are monosaccha-
rides, that is, they have a molecular structure which allows
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intestinal absorption without additional enzymatic degra-
dation. Improvement of nutritional status and alteration in
ileo-colonic flora by certain foods is theorized to lead to de-
creased mucosal inflammation [2,45]. There has been an in-
crease in publications over the past ten years with regard to
food-based strategies used to alter the intestinal microflora
as an alternative or adjunctive therapy for the treatment of
IBD. The altered bacteria in the microbiome of IBD pa-
tients is said to drive inflammatory responses, [21,24] and
there are a growing number of articles linking particular
foods that influence the intestinal microbiome, by with-
holding certain foods that are not well tolerated by patients,
or introducing others that can improve symptoms [46].
The dietary pattern of the IBD-AID is carefully ori-
ented to decrease inflammation [14,15] and improve nu-
tritional status, and thought to maintain a beneficial
intestinal bacterial balance; however, this has yet to be
proven by rigorous scientific examination. The current
case series is promising, but must be followed with
rigorous research and standardized study design to de-
tect molecular markers of inflammatory and histo-
pathological changes to correlate with clinical outcomes.
The IBD-AID can be difficult and restrictive diet; with
adherence largely dictated by personal motivation, sup-
port from family and friends, and skills in the kitchen
and the marketplace. Consultation and continued sup-
port from a knowledgeable dietitian may enhance com-
pliance with the diet.
Conclusion
Physicians are not provided with specific dietary treat-
ments to offer their IBD patients [47], and recommenda-
tions for normal diet are often based upon a philosophy
of “if it hurts, don’t do it”. This case series serves to
highlight the importance of dietary manipulation as an
adjunct to the limited existing management options for
IBD. The study of the IBD-AID would benefit from the
rigorous analysis provided by a randomized clinical trial,
with evaluation of mucosal healing and assessment of
change in gut flora to examine the exact mechanism(s)
of benefit.
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